Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02332629
Other study ID # HK_VL_08_2014a
Secondary ID
Status Completed
Phase Phase 3
First received January 5, 2015
Last updated April 7, 2016
Start date January 2015
Est. completion date April 2016

Study information

Verified date April 2016
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Health and Medicines Authority
Study type Interventional

Clinical Trial Summary

This study evaluates the pathophysiological effects of a single dose methylprednisolone administered prior to total knee-arthroplasty surgery (TKA). The investigators examine the effect on the endothelial glycocalyx shedding due to surgical trauma.

Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will receive placebo.

The investigators hypothesize that the group receiving methylprednisolone will experience reduction in glycocalyx degradation compared to the placebo-group, early after TKA.


Description:

The anti-inflammatory effects of glucocorticoids are well known. The beneficial effects on postoperative pain, postoperative nausea and vomiting are well-documented.

Postoperatively, activation and / or dysregulation of the inflammatory system influence on the endothelial glycocalyx. Damage of the vascular endothelia increases the risk of cardiovascular and thromboembolic complications.

In animal studies glucocorticoids have been found to preserve the endothelial glycocalyx and the vascular barrier.

The effect of glucocorticoids on human endothelial glycocalyx after surgery is unknown and calls for further investigation.

This study is embedded in a primary study registrated as: NCT02319343

For further details please view the EudraCT registration:

EudraCT nr.: 2014-003395-23


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 55 Years to 80 Years
Eligibility Inclusion Criteria:

- Osteoarthrosis

- Undergoing total unilateral knee-arthroplasty surgery

- Speak and understand Danish

- Have given informed consent

Exclusion Criteria:

- Revision, bilateral og uni chamber knee-arthroplasty surgery

- General anaesthesia

- Allergy or intolerance towards Methylprednisolone

- Local or systemic infection

- Permanent systemic treatment with steroids within 30 days preoperatively

- Insulin-dependent diabetes

- Active treatment of ulcer within 3 months preoperatively

- Cancer disease

- Autoimmune disease incl. rheumatoid arthritis

- Pregnant or breast feeding women

- Menopause <1 year

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
Methylprednisolone
Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
Isotonic Sodium Chloride
Placebo

Locations

Country Name City State
Denmark Bispebjerg Hospital Copenhagen NV

Sponsors (2)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Bispebjerg Hospital

Country where clinical trial is conducted

Denmark, 

References & Publications (10)

Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol. 2009 Jan;104(1):78-89. doi: 10.1007/s00395-008-0749-5. Epub 2008 Oct 3. — View Citation

Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, Welsch U, Becker BF. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007 Nov;107(5):776-84. — View Citation

Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593. Review. — View Citation

Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011 Aug;254(2):194-200. doi: 10.1097/SLA.0b013e318226113d. — View Citation

Kehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X. — View Citation

Khan SK, Malviya A, Muller SD, Carluke I, Partington PF, Emmerson KP, Reed MR. Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop. 2014 Feb;85(1):26-31. doi: 10.3109/17453674.2013.874925. Epub 2013 Dec 20. — View Citation

Malviya A, Martin K, Harper I, Muller SD, Emmerson KP, Partington PF, Reed MR. Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop. 2011 Oct;82(5):577-81. doi: 10.3109/17453674.2011.618911. Epub 2011 Sep 6. — View Citation

Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012 Jul;73(1):60-6. doi: 10.1097/TA.0b013e31825b5c10. — View Citation

Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Reichart B, Peter K, Becker BF. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007 Oct 23;116(17):1896-906. Epub 2007 Oct 8. — View Citation

Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012 Mar;108(3):384-94. doi: 10.1093/bja/aer515. Epub 2012 Jan 29. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in plasma Syndecan-1 from baseline (before surgery) to 24 hours after surgery baseline to 24 hours No
Secondary Change in plasma soluble Thrombomodulin from baseline (before surgery) to 24 hours after surgery baseline to 24 hours No
Secondary Change in plasma SE-Selectin from baseline (before surgery) to 24 hours after surgery One day after surgery No
Secondary Change in plasma VE-Cadherin from baseline (before surgery) to 24 hours after surgery baseline to 24 hours No
See also
  Status Clinical Trial Phase
Completed NCT02445898 - Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02542592 - Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02910830 - Osteoarthritis Relationships and Tobacco " Ancillary Study Khoala " N/A
Completed NCT01443975 - Clinical Evaluation on the Use of the X-pander Device N/A
Completed NCT01603017 - Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis N/A
Completed NCT02222740 - A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain Phase 2
Completed NCT00860873 - Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis Phase 3
Recruiting NCT02923310 - Evaluation of Two Types of PRP in Knee Osteoarthritis Phase 1/Phase 2
Active, not recruiting NCT02518269 - A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty N/A
Completed NCT03093038 - Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study. N/A
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Withdrawn NCT02341079 - Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty Phase 2/Phase 3
Completed NCT00291499 - Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand Phase 3
Recruiting NCT05882227 - Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program. N/A
Completed NCT05697952 - E1K Intra Articular(IA) Treatment for Knee Osteoarthritis Phase 2
Completed NCT01940692 - Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA Phase 2
Completed NCT02071745 - Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results N/A
Completed NCT02319343 - Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332616 - Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332603 - Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty Phase 3